4-Chlorophenylboronic acid

We are 4-Chlorophenylboronic acid CAS:1679-18-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Product Name: 4-Chlorophenylboronic acid
Other Name:
4-Chlorophenylboronic acid
para-chlorophenylboronic acid
para-chlorobenzene boronic acid
(4-Chlorophenyl)boronic acid
4-CHLOROPHENYLBORNIC ACID
4-Chlorobenzeneboronic Acid
p-chlorophenylboronic acid
p-chlorobenzeneboronic acid
CAS No: 1679-18-1
MF: C6H6BClO2
MW: 156.37500
Density: 1.32g/cm3
Boiling point: 295.4ºC
Melting point: 284-289 °C(lit.)
Flash point: 132.4ºC
Refractive index: 1.557
UN Number:  Not dangerous goods.
UN Proper Shipping Name:  Not dangerous goods.
Transport hazard class:  Not dangerous goods.
Packing group:  Not dangerous goods.
 
Specification
Appearance: White to off-white powder
Assay: ≥98.0%
Water: ≤0.50%
 
Application
1. Venetoclax/ABT-199 intermediate.
2. Vemurafenib intermediate.
3. For the double Suzuki coupling reaction to synthesize substituted diarylmethylene hydrazine, etc.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

4-Chlorophenylboronic acid


Related News: China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.(4R, 5S) -5- (3,5-bis (trifluorometil) fenil) -4-metiloxazolidin-2-ona CAS:875444-08-9 China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.68239-81-6 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.99-99-0 Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS.From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.

Related Products
Product Name
4-Chloronitrobenzene View Details
Diethylphosphorodithioate View Details
1-Amino-2-(isopropylsulphonyl)benzene View Details
6-amino-4-chloro-7-ethoxyquinoline-3-carbonitrile manufacturer H-Glu(H-Lys-OH)-OH manufacturer Hexanedione manufacturer 2-Amino-4′-fluorobenzophenone manufacturer 2-aminopropanediamide manufacturer